

In the Specification

Applicant presents replacement paragraphs below indicating the changes with insertions indicated by bracketing and deletions indicated by strikeouts.

Please replace paragraph beginning at page 24, line 22 with the amended paragraph/line as follows:

Polyclonal antibody UVT59: A synthetic peptide corresponding to residues 496-515 of TgAMA-1 (acetyl-EFQSDRGARKKRPSDLMQEAG-amide (SEQ ID NO: 3)) was coupled to keyhole limpet hemocyanin using the Imject Maleimide Activated mcKLH Kit (Pierce, Rockford IL). The peptide-carrier conjugate was used to generate rabbit polyclonal antisera (Cocalico Biologicals Inc., Reamstown PA); serum titers were determined by western blot and immunofluorescence microscopy. Synthetic peptide coupled to agarose using the SulfoLink Kit (Pierce) was used to affinity purify AMA-1-specific antibody UVT59 from total serum as recommended by the manufacturer, except that 0.01 vol of stock protease inhibitors (aqueous stock contains 2mg/ml aprotinin, 2mg/ml leupeptin, 16mg/ml benzamidine, and 5mg/ml 4-(2-aminoethyl)-phenylsulfonylfluoride; DMSO stock contains 5mg/ml pepstatin) were added to the serum before applying it to the peptide column.

Please replace line 1 on page 35, with the amended line as follows: Claims [What is claimed is]